RxDoctor Payments Data

Paul Schurmann, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1609067560

Payments from drug & device makers

$80,430in general payments, 2019–2025

Across 897 payments — averaging $89.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Respicardia, Inc.$38K
  • Medtronic$18K
  • Abbott$9K
  • Biosense Webster, Inc.$6K
  • Baylis Medical Company Inc$3K
  • Boston Scientific$2K
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$10,50013%
  • Speaking & faculty fees$31,20039%
  • Travel & lodging$9,70212%
  • Food & beverage$28,86736%
  • Education$1610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,430 in reported general payments places this provider in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$192,290
Medicare patients
2,353
Services billed
3,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$400,675
XareltoRivaroxaban104$122,807
MultaqDronedarone Hcl39$53,811
EntrestoSacubitril/Valsartan27$28,926
FarxigaDapagliflozin Propanediol14$13,715
Dofetilide65$8,876
Metoprolol Succinate239$3,781
Amiodarone Hcl69$1,038
Carvedilol90$948
Atorvastatin Calcium72$873
SotalolSotalol Hcl26$825
Metoprolol Tartrate72$695
Losartan Potassium68$687
Digoxin21$663
ClopidogrelClopidogrel Bisulfate75$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$400,675329 claims
Johnson & JohnsonXarelto$49$122,807104 claims
Sanofi-aventis U.S. LLCMultaq$48$53,81139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →